PL
BPMC

Polianta Ltd’s Blueprint Medicines BPMC Stock Holding History

Polianta Ltd’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,200
Closed -$1.25M – 71
2021
Q2 		$1.25M Buy
14,200
+2,200
+18% +$202K 0.65% 21
2021
Q1 		$1.17M Buy
12,000
+1,400
+13% +$140K 0.65% 34
2020
Q4 		$1.19M Buy
+10,600
New +$1.12M 0.66% 46
2019
Q3 		– Sell
-13,700
Closed -$1.29M – 67
2019
Q2 		$1.29M Buy
+13,700
New +$1.13M 0.56% 14

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Polianta Ltd's BPMC Position: Q3 2021 in Review

Polianta Ltd sold out of Blueprint Medicines (BPMC) in Q3 2021, closing a stake of 14,200 shares — an estimated $1.25M sold.

Polianta Ltd first reported a position in BPMC in Q2 2019 and held it in 4 quarters. The position peaked at $1.29M in Q2 2019. 288 funds tracked by Wall St. Rank hold BPMC as of Q3 2021.

  • Polianta Ltd reported no remaining Blueprint Medicines position as of Q3 2021 after selling out during the quarter.
  • Polianta Ltd sold 14,200 Blueprint Medicines shares in Q3 2021, an estimated $1.25M.
  • Polianta Ltd first reported a position in Blueprint Medicines in Q2 2019 and held it in 4 quarters.
  • Polianta Ltd's Blueprint Medicines position peaked at $1.29M in Q2 2019.
  • 288 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2021.

Based on Polianta Ltd's 13F filing for Q3 2021, filed 19 Oct 2021.